{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:17:39Z","timestamp":1772183859758,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.leukres.2008.05.011","type":"journal-article","created":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T22:23:25Z","timestamp":1216160605000},"page":"1800-1808","source":"Crossref","is-referenced-by-count":28,"title":["Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years"],"prefix":"10.1016","volume":"32","author":[{"given":"Anna","family":"Candoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Toffoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Chiarvesio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Paolo","family":"Piccaluga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Michelutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.05.011_bib1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia, review article","volume":"341","author":"L\u00f6wenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.05.011_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2004.1.98","article-title":"Acute myeloid leukemia","volume":"1","author":"Stone","year":"2004","journal-title":"Haematology"},{"key":"10.1016\/j.leukres.2008.05.011_bib3","first-page":"1015","article-title":"Therapy of acute myeloid leukemia: towards a patient-oriented, risk adapted approach","volume":"83","author":"Mandelli","year":"1998","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.leukres.2008.05.011_bib4","first-page":"513","article-title":"High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia","volume":"81","author":"Clavio","year":"1996","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2008.05.011_bib5","first-page":"481","article-title":"Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose Ara-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients","volume":"21","author":"Clavio","year":"2002","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.leukres.2008.05.011_bib6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1365-2141.1997.4763281.x","article-title":"Fludarabine., cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia","volume":"99","author":"Parker","year":"1997","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.leukres.2008.05.011_bib7","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","article-title":"Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin+\/\u2212all-trans retinoic acid+\/\u2212granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"93","author":"Estey","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2141.2001.02551.x","volume":"112","author":"Jackson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/sj.thj.6200392","article-title":"Use of fludarabine in the treatment of acute myeloid leukemia","volume":"5","author":"Jackson","year":"2004","journal-title":"Hematol J"},{"key":"10.1016\/j.leukres.2008.05.011_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2141.2003.04728.x","article-title":"Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukemia or myelodysplastic syndromes","volume":"124","author":"Virchis","year":"2004","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.leukres.2008.05.011_bib11","first-page":"776","article-title":"Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia","volume":"90","author":"Ferrara","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.05.011_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/10428190109057932","article-title":"Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia","volume":"40","author":"Russo","year":"2001","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.leukres.2008.05.011_bib13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2141.2005.05745.x","article-title":"Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients","volume":"131","author":"Russo","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.2006.06390.x","article-title":"Case\u2013control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukemia patients","volume":"136","author":"Malagola","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib15","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.leukres.2008.05.011_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2004.06.010","article-title":"Gemtuzumab ozogamicin: a component of induction therapy in AML?","volume":"29","author":"Giles","year":"2005","journal-title":"Leukemia Res"},{"issue":"4","key":"10.1016\/j.leukres.2008.05.011_bib17","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","article-title":"The role of gemtuzumab ozogamicin in acute leukemia therapy","volume":"132","author":"Tsimberidou","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Spencer CM. Gemtuzumab Ozogamicin","volume":"61","author":"Mcgavin","year":"2001","journal-title":"Drugs"},{"issue":"25","key":"10.1016\/j.leukres.2008.05.011_bib20","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/sj.onc.1210364","article-title":"The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients","volume":"26","author":"Pagano","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2008.05.011_bib21","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib22","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33 positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.leukres.2008.05.011_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.806","article-title":"The role of MDR-related proteins in the prognosis of adult acute myeloid leukemia (AML) with normal karyotype","volume":"25","author":"Damiani","year":"2007","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.leukres.2008.05.011_bib24","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1038\/sj.leu.2402675","article-title":"Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients","volume":"16","author":"Cilloni","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.05.011_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000077562","article-title":"WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndromes","volume":"112","author":"Cilloni","year":"2004","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: biology and treatment","volume":"1","author":"Small","year":"2006","journal-title":"Haematology"},{"key":"10.1016\/j.leukres.2008.05.011_bib27","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.05.011_bib28","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJM199501263320403","article-title":"Autologous and allogeneic bone marrow transplantation versus intensive chemotherapy in acute myelogenous leukemia","volume":"332","author":"Zittoun","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.05.011_bib29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia in first complete remission: an intention to treat analysis of the EORTC\/GIMEMA AML-10 trial","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib30","first-page":"143","article-title":"Effect of fludarabine and arabinosyl cytosine on multidrug resistant cells","volume":"82","author":"Michelutti","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.05.011_bib31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1365-2141.1999.01172.x","article-title":"P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non lymphocytic leukemias: biological and clinical implications","volume":"104","author":"Michieli","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1703602","article-title":"Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease","volume":"30","author":"Cohen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2008.05.011_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-002-0539-y","article-title":"Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia","volume":"50","author":"Cortes","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2008.05.011_bib34","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood.V99.12.4343","article-title":"Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00280-002-0546-z","article-title":"Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia","volume":"51","author":"Alvarado","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2008.05.011_bib36","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0145-2126(03)00021-3","article-title":"Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia","volume":"27","author":"Apostolidou","year":"2003","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2008.05.011_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2004.04.011","article-title":"Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older","volume":"29","author":"Nabhan","year":"2005","journal-title":"Leukemia Res"},{"issue":"13","key":"10.1016\/j.leukres.2008.05.011_bib38","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","article-title":"A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia","volume":"102","author":"Kell","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2008.05.011_bib39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2141.2007.06646.x","volume":"138","author":"Clavio","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cncr.11239","article-title":"Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high risk myelodysplastic syndromes","volume":"97","author":"Tsimberidou","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2008.05.011_bib41","first-page":"339","article-title":"Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease following treatment with gemtuzumab ozogamicin","volume":"100","author":"Erba","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V108.11.13.13","article-title":"The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial","volume":"108","author":"Burnett","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000100992","article-title":"Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients","volume":"118","author":"Pirrotta","year":"2007","journal-title":"Acta Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib44","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2003-02-0396","article-title":"Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells","volume":"102","author":"Walter","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.05.011_bib45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"Van Der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.05.011_bib46","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2141.2004.04952.x","article-title":"WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukemia patients-results from a single-centre study","volume":"125","author":"Ostergaard","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.05.011_bib47","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/sj.leu.2402512","article-title":"Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry","volume":"16","author":"Trka","year":"2002","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T09:26:35Z","timestamp":1709112395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608002506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0145212608002506"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.05.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}